Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 39, 2009, Pages 16823-16828

  Kamil, Jeremy P ^a   Hume, Adam J ^b   Jurak, Igor ^a   Münger, Karl ^a,c   Kalejta, Robert F ^b   Coen, Donald M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiviral drugs; Cell cycle; Cyclin dependent kinase; E2F; Retinoblastoma protein

Indexed keywords

PROTEIN E7; PROTEIN KINASE; PROTEIN KINASE UL 97; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; VIRUS GENE; VIRUS INFECTION; VIRUS REPLICATION;

DNA, VIRAL; GENES, VIRAL; HUMANS; ONCOGENE PROTEINS, VIRAL; PHOSPHORYLATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RETINOBLASTOMA PROTEIN; VIRUS REPLICATION;

DNA VIRUSES; HUMAN HERPESVIRUS 5; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 70349730029     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0901521106     Document Type: Article

References (58)

1. Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10:699-703.
2. Helt AM, Galloway DA (2003) Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24:159-169.
3. Hume AJ, Kalejta RF (2009) Regulation of the retinoblastoma proteins by the human herpesviruses. Cell Div 4:1.
4. Boyer SN, Wazer DE, Band V (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56:4620-4624.
5. Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937. (Pubitemid 19066153)
6. Jones DL, Munger K (1997) Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 71:2905-2912.
7. Hume AJ, et al. (2008) Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 320:797-799. (Pubitemid 351929629)
8. Prichard MN, et al. (2008) Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol 82:5054-5067.
9. Mocarski ES, Shenk T, Pass RF (2007) Cytomegaloviruses. In Fields' Virology, eds Knipe DM, Howley PM (Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia), 5th Ed, pp 2701-2772.
10. Biron KK, et al. (2002) Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 46:2365-2372.
11. Lalezari JP, et al. (2002) Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother 46:2969-2976.
12. Littler E, Stuart AD, Chee MS (1992) Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
13. Sullivan V, et al. (1992) A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
14. Dunn W, et al. (2003) Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci USA 100:14223-14228. (Pubitemid 37499218)
15. Krosky PM, Baek MC, Coen DM (2003) The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol 77:905-914.
16. Prichard MN, et al. (1999) A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 73:5663-5670.
17. Wolf DG, Courcelle CT, Prichard MN, Mocarski ES (2001) Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc Natl Acad Sci USA 98:1895-1900.
18. Kamil JP, Coen DM (2007) Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65. J Virol 81:10659-10668.
19. Azzeh M, Honigman A, Taraboulos A, Rouvinski A, Wolf DG (2006) Structural changes in human cytomegalovirus cytoplasmic assembly sites in the absence of UL97 kinase activity. Virology 354:69-79. (Pubitemid 44441507)
20. Prichard MN, Britt WJ, Daily SL, Hartline CB, Kern ER (2005) Human cytomegalovirus UL97 kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol 79:15494-15502.
21. Hobom U, Brune W, Messerle M, Hahn G, Koszinowski UH (2000) Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: Mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol 74:7720-7729. (Pubitemid 30641615)
22. Jones DL, Thompson DA, Munger K (1997) Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 239:97-107.
23. Phelps WC, Munger K, Yee CL, Barnes JA, Howley PM (1992) Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol 66:2418-2427.
24. Jault FM, et al. (1995) Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol 69:6697-6704.
25. Wade M, Kowalik TF, Mudryj M, Huang ES, Azizkhan JC (1992) E2F mediates dihydrofolate reductase promoter activation and multiprotein complex formation in human cytomegalovirus infection. Mol Cell Biol 12:4364-4374.
26. Browne EP, Wing B, Coleman D, Shenk T (2001) Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: Viral block to the accumulation of antiviral mRNAs. J Virol 75:12319-12330. (Pubitemid 33115904)
27. Song YJ, Stinski MF (2002) Effect of the human cytomegalovirus IE86 protein on expression of E2F-responsive genes: A DNA microarray analysis. Proc Natl Acad Sci USA 99:2836-2841.
28. DeGregori J, Kowalik T, Nevins JR (1995) Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 15:4215-4224.
29. Ren B, et al. (2002) E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 16:245-256. (Pubitemid 34075816)
30. Marschall M, Freitag M, Weiler S, Sorg G, Stamminger T (2000) Recombinant green fluorescent protein-expressinghumancytomegalovirus as a tool for screening antiviral agents. Antimicrob Agents Chemother 44:1588-1597. (Pubitemid 30340800)
31. Depto AS, Stenberg RM (1992) Functional analysis of the true late human cytomegalovirus pp28 upstream promoter: Cis-acting elements and viral trans-acting proteins necessary for promoter activation. J Virol 66:3241-3246.
32. Marschall M, et al. (2005) Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J Biol Chem 280:33357-33367. (Pubitemid 41397133)
33. Hamirally S, et al. (2009) Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog 5:e1000275.
34. Lee CP, et al. (2008) Epstein-Barr virus BGLF4 kinase induces disassembly of the nuclear lamina to facilitate virion production. J Virol 82:11913-11926.
35. O'Brien V (1998) Viruses and apoptosis. J Gen Virol 79:1833-1845.
36. Chou S, Van Wechel LC, Marousek GI (2006) Effect of cell culture conditions on the anticytomegalovirus activity of maribavir. Antimicrob Agents Chemother 50:2557-2559. (Pubitemid 43993205)
37. Hertel L, Chou S, Mocarski ES (2007) Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS pathogens 3:e6. (Pubitemid 46172387)
38. Polyak K, et al. (1994) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9-22. (Pubitemid 2042846)
39. Reynisdottir I, Polyak K, Iavarone A, Massague J (1995) Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9:1831-1845.
40. Gill RB, Frederick SL, Hartline CB, Chou S, Prichard MN (2009) Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virology J 6:9.
41. Botz J, et al. (1996) Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol 16:3401-3409. (Pubitemid 26199859)
42. Geng Y, et al. (1996) Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12:1173-1180. (Pubitemid 26127247)
43. Ohtani K, DeGregori J, Nevins JR (1995) Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 92:12146-12150. (Pubitemid 26014027)
44. Bresnahan WA, Boldogh I, Thompson EA, Albrecht T (1996) Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. Virology 224:150-160. (Pubitemid 26358110)
45. Dyson N, Guida P, Munger K, Harlow E (1992) Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 66:6893-6902.
46. Pardee AB (1989) G1 events and regulation of cell proliferation. Science 246:603-608.
47. Wang LH, et al. (2003) Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 47:1334-1342.
48. Trofe J, Pote L, Wade E, Blumberg E, Bloom RD (2008) Maribavir: A novel antiviral agent with activity against cytomegalovirus. Ann Pharmacother 42:1447-1457.
49. Michaelis M, Doerr HW, Cinatl J (2009) The story of human cytomegalovirus and cancer: Increasing evidence and open questions. Neoplasia 11:1-9.
50. Prins RM, Cloughesy TF, Liau LM (2008) Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 359:539-541.
51. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R (2008) Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116:79-86.
52. Cobbs CS, et al. (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62:3347-3350. (Pubitemid 34651375)
53. Huh KW, et al. (2005) Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sci USA 102:11492-11497.
54. Tischer BK, von Einem J, Kaufer B, Osterrieder N (2006) Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40:191-197. (Pubitemid 46542640)
55. Blankenship CA, Shenk T (2002) Mutant human cytomegalovirus lacking the immediate-early TRS1 coding region exhibits a late defect. J Virol 76:12290-12299.
56. Yu D, Smith GA, Enquist LW, Shenk T (2002) Construction of a self-excisable bacterial artificial chromosome containing the human cytomegalovirus genome and mutagenesis of the diploid TRL/IRL13 gene. J Virol 76:2316-2328. (Pubitemid 34150700)
57. Nguyen CL, Eichwald C, Nibert ML,Munger K (2007) Human papillomavirus type 16 E7 oncoprotein associates with the centrosomal component gamma-tubulin. J Virol 81:13533-13543. (Pubitemid 350247847)
58. Jurak I, Brune W (2006) Induction of apoptosis limits cytomegalovirus cross-species infection. EMBO J 25:2634-2642. (Pubitemid 44012245)